Partha Pratim Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Partha Pratim Das has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Bin E. Li
8 shared publications- Cong Peng
Nanjing University of Aeronautics and Astronautics
8 shared publications - Elenoe C. Smith
Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA
8 shared publications - Giulia Cheloni
Department of Experimental and Clinical Biomedical Sciences, Università degli Studi di Firenze, Florence, Italy
8 shared publications - Huafeng Xie
Department of Hematology, Guangzhou First People's Hospital, Institutes for Life Sciences and School of Medicine, South China University of Technology, Guangzhou, China
8 shared publications - Jialiang Huang
Australian Centre for Advanced Photovoltaics, School of Photovoltaic and Renewable Energy Engineering, University of New South Wales, Sydney, Australia
8 shared publications
Latest Publications
- 13 February 2025
- Published by Taylor & Francis
- p. 1-17
Past, Present, and Future of Emerging Oncogenic Viral Infections
Cancer is a disease that can be caused by infectious agents like bacteria, parasites, and viruses. Viral infections can be attributed to over 17% of cancer cases recorded across the world. This chapter offers an examination of the historical, current, and potential future trajectories of emerging oncogenic viral infections, with a focus on notable viruses including human papillomavirus (HPV), Epstein–Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), and human T-cell lymphotropic virus type 1 (HTLV-1). Oncogenic viruses can cause mutations in critical genes and/or alter several pathways that regulate the hallmarks of cancers like genomic stability, suppression of apoptosis, and modulation of immune system. The traditional therapeutic modalities for oncogenic viral infections include vaccination, radiotherapy, targeted therapy, and immune-oncotherapy. Newer emerging virus variants have been under study for their potential to promote cancers in the infected host cells. The interplay between viral infections and host immune responses highlights the need for immunotherapeutic approaches in managing virus-associated cancers. Several new vaccines, targeted drugs against viral proteins, and polyphenols against viral proteins are being currently investigated as potential answers against oncogenic viral infections.
- 13 February 2025
- Published by Taylor & Francis
- p. 1-17
Past, Present, and Future of Emerging Oncogenic Viral Infections
Cancer is a disease that can be caused by infectious agents like bacteria, parasites, and viruses. Viral infections can be attributed to over 17% of cancer cases recorded across the world. This chapter offers an examination of the historical, current, and potential future trajectories of emerging oncogenic viral infections, with a focus on notable viruses including human papillomavirus (HPV), Epstein–Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), and human T-cell lymphotropic virus type 1 (HTLV-1). Oncogenic viruses can cause mutations in critical genes and/or alter several pathways that regulate the hallmarks of cancers like genomic stability, suppression of apoptosis, and modulation of immune system. The traditional therapeutic modalities for oncogenic viral infections include vaccination, radiotherapy, targeted therapy, and immune-oncotherapy. Newer emerging virus variants have been under study for their potential to promote cancers in the infected host cells. The interplay between viral infections and host immune responses highlights the need for immunotherapeutic approaches in managing virus-associated cancers. Several new vaccines, targeted drugs against viral proteins, and polyphenols against viral proteins are being currently investigated as potential answers against oncogenic viral infections.
- 22 October 2022
- Published by Wiley in Reproduction in Domestic Animals
- Vol. 58 (2) , 219-229
Propagation of porcine spermatogonial stem cells in serum‐free culture conditions using knockout serum replacement
In vitro culture and expansion of spermatogonial stem cells (SSCs) is an essential prerequisite to enhancing livestock productivity through SSC transplantation. Most of the culture media have been observed to be supplemented with serum. However, the use of serum in culture media may exert detrimental effects on SSC maintenance in vitro. An attempt was made to culture SSCs by replacing serum with 5% ‘Knockout Serum Replacement (KSR)’ in Doom pig (Sus domesticus), one of the valued indigenous germplasm of North‐East India. Testes from 7 to 15 days old piglets were used for isolation, enrichment and in vitro culture of putative SSCs using serum‐based and serum‐free culture media. The cells were characterized for SSC‐specific pluripotent markers expression by immunofluorescence staining and quantitative real‐time PCR. The diameter and number of SSC colonies were recorded on days 9, 20 and 30 of culture. Similar morphologies of the SSC colonies were observed in both serum‐based and serum‐free culture conditions. Colony diameter and colony number were non‐significantly higher in serum‐free than serum‐based media. The cells from both the culture conditions showed high alkaline phosphatase activity. The expression of SSC‐specific pluripotent markers was observed in immunofluorescence and quantitative real‐time PCR study. The present study revealed that SSCs from porcine species could be maintained in vitro for up to 30 days in serum‐free culture using 5% KSR, which is believed to be a promising protein source for improving livestock production, and health care along with their conservation.
- 22 October 2022
- Published by Wiley in Reproduction in Domestic Animals
- Vol. 58 (2) , 219-229
Propagation of porcine spermatogonial stem cells in serum‐free culture conditions using knockout serum replacement
In vitro culture and expansion of spermatogonial stem cells (SSCs) is an essential prerequisite to enhancing livestock productivity through SSC transplantation. Most of the culture media have been observed to be supplemented with serum. However, the use of serum in culture media may exert detrimental effects on SSC maintenance in vitro. An attempt was made to culture SSCs by replacing serum with 5% ‘Knockout Serum Replacement (KSR)’ in Doom pig (Sus domesticus), one of the valued indigenous germplasm of North‐East India. Testes from 7 to 15 days old piglets were used for isolation, enrichment and in vitro culture of putative SSCs using serum‐based and serum‐free culture media. The cells were characterized for SSC‐specific pluripotent markers expression by immunofluorescence staining and quantitative real‐time PCR. The diameter and number of SSC colonies were recorded on days 9, 20 and 30 of culture. Similar morphologies of the SSC colonies were observed in both serum‐based and serum‐free culture conditions. Colony diameter and colony number were non‐significantly higher in serum‐free than serum‐based media. The cells from both the culture conditions showed high alkaline phosphatase activity. The expression of SSC‐specific pluripotent markers was observed in immunofluorescence and quantitative real‐time PCR study. The present study revealed that SSCs from porcine species could be maintained in vitro for up to 30 days in serum‐free culture using 5% KSR, which is believed to be a promising protein source for improving livestock production, and health care along with their conservation.